KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Total Debt: 2011-2019

Historic Total Debt for Nektar Therapeutics (NKTR) over the last 9 years, with Dec 2019 value amounting to $502.9 million.

  • Nektar Therapeutics' Total Debt rose 105.73% to $508.9 million in Q1 2020 from the same period last year, while for Mar 2020 it was $508.9 million, marking a year-over-year increase of 105.73%. This contributed to the annual value of $502.9 million for FY2019, which is 103.64% up from last year.
  • Per Nektar Therapeutics' latest filing, its Total Debt stood at $502.9 million for FY2019, which was up 103.64% from $246.9 million recorded in FY2018.
  • Nektar Therapeutics' Total Debt's 5-year high stood at $502.9 million during FY2019, with a 5-year trough of $241.7 million in FY2015.
  • Its 3-year average for Total Debt is $331.7 million, with a median of $246.9 million in 2018.
  • Data for Nektar Therapeutics' Total Debt shows a peak YoY surged of 103.64% (in 2019) over the last 5 years.
  • Nektar Therapeutics' Total Debt (Yearly) stood at $241.7 million in 2015, then climbed by 0.73% to $243.5 million in 2016, then increased by 0.72% to $245.2 million in 2017, then increased by 0.71% to $246.9 million in 2018, then surged by 103.64% to $502.9 million in 2019.